GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
Go back to GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 288.18 +1.77 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $286.41 | 52 Week High | $109.10 | |||
| Open | $290.89 | 52 Week Low | $31.38 | |||
| Day High | $291.95 | P/E | N/A | |||
| Day Low | $285.26 | EPS | $-1.45 | |||
| Volume | 1,087,832 | |||||
